SlideShare ist ein Scribd-Unternehmen logo
1 von 4
Downloaden Sie, um offline zu lesen
Healthcare
In-Depth Report Series




          OTC Drugs:
          U.S. Competitor Cost Structures 2010



          8th Edition
          One of Kline's series of reports on competitor cost structures

          Published September 2010
          Base Year: 2008 and 2009

                                         An accurate and comprehensive examination of competitor cost
                                         structures of leading OTC marketers, focusing on key trends,
                                         developments, and business opportunities designed to:


                                             Understand how key marketers' cost structures have changed
                                             during the recession
                                             Offer a benchmark for industry cost performance
                                             Reveal profit and loss line items for each players' OTC business
                                             and their largest product classes
                                             Assess the cost positions of market leaders including Johnson &
                                             Johnson, Pfizer, Bayer Group, and GlaxoSmithKline
                                             Give subscribers critical insights in order to succeed in the face of
                                             intensifying cost pressures
                                             Provide an appraisal of expected future performance




  www.KlineGroup.com
  Report #Y617B | © 2011 Kline & Company, Inc.
OTC Drugs:
U.S. Competitor Cost Structures 2010


   Report Scope
   OTC Drugs: U.S. Competitor Cost Structures 2010 has been successfully completed seven times before and was last
   published in 2006. The report presents information on the financial performance, profitability, and costs structures
   of the ten leading OTC companies in the United States. It is designed to help OTC pharmaceutical companies
   benchmark their cost structures with those of their competitors. For each company, cost breakdowns are provided
   for its overall OTC business, as well as its leading product classes.


   Company profiles also feature overviews of each company's OTC business unit, an assessment of domestic OTC
   sales by product class, and analysis of costs, expenses, and profitability.


   Cost structures refer to U.S. operations only. Sales, expenses, and profits are presented for 2008 and 2009 and do
   not include extraordinary or nonrecurring items reports in published financial statements. References to overall
   corporate results are for the latest fiscal year available.




   Key Benefits
   This study provides subscribers with accurate and concise profitability information and cost structures of 10 major
   OTC marketers in the United States. It is designed to help nonprescription drugs firms benchmark their cost
   structures with those of their competitors.


   Specifically, this report assists subscribers by providing:


       Line-item detail to allow companies to benchmark their business against that of competitors
       Details on how OTC marketers structure and run their operations
       Insights into decisions companies have made regarding outsourcing, resource allocation, and product portfolios
       Competitive intelligence that helps companies make decisions to take steps to lower costs
       Important comparisons of marketers' cost structures between 2005, 2008, and 2009 and understanding how
       OTC marketers are coping with the recession by shifting their costs




  www.KlineGroup.com                                                             Report #Y617B | © 2011 Kline & Company, Inc.
OTC Drugs:
U.S. Competitor Cost Structures 2010


  Report Contents
  1.   INTRODUCTION

  2.   EXECUTIVE SUMMARY
           State of the industry
           Impacts on the industry from the recession
           Market sales and growth
           Industry cost structure
           Key factors influencing profitability
           Analysis of key expenses
           Competitive landscape/ impact of mergers on costs structures
           Product class cost structures (for those listed in Table 1)
           Appraisal and Outlook

  3.   COMPANY PROFILES
       For each of the companies profiled (listed in Table 2), the report provides information on profitability for its OTC business unit and
       leading product classes (illustrated in Table 3) and includes:
           Corporate overview
           Corporate sales and profits
           Business unit cost structure
           – Profitability
           – Analysis of key expenses
           Cost structure of leading product classes
           Appraisal




                        Table 1: Product Classes Covered                                           Table 3: Cost Structure of the OTC Industry


                                                                                                             Line item                % Of net sales
       Allergy, asthma,                      Nutritional products
                                                                                          NET SALES
       and sinus medications                 Topical products                             COST OF GOODS SOLD
       Cough and cold preparations           Other products, including home                Raw materials
       Digestive products                    diagnostic test kits, sleeping                Packaging
                                             aids, smoking cessation aids,                 Processing
       Feminine products                                                                   Overhead
                                             and weight loss medications
       Internal analgesics                                                                 Total
                                                                                          GROSS MARGIN
                                                                                          MARKETING EXPENSES
                                                                                           Promotion
                                                                                            Trade
                                                                                            Consumer
                          Table 2: Companies Profiled
                                                                                            Total
                                                                                           Advertising
             Bayer Group                       Perrigo                                     Marketing department
             GlaxoSmithKline                   Pfizer                                      Sales force/sampling
                                                                                           Distribution
             Johnson & Johnson                 Procter & Gamble
                                                                                           Total
             Merck                             Reckitt Benckiser
                                                                                          MARGIN AFTER MARKETING EXPENSES
             Novartis                          Sanofi-Aventis                             OTHER OPERATING EXPENSES
                                                                                          Administration
                                                                                          Research and development
                                                                                          Total
                                                                                          OPERATING MARGIN




   www.KlineGroup.com                                                                               Report #Y617B | © 2011 Kline & Company, Inc.
OTC Drugs:
U.S. Competitor Cost Structures 2010


   Methodology
   Kline is unmatched in our ability to gather hard-to-get market and competitive intelligence with a high degree of
   confidence. Kline's approach relies heavily on primary research, employing the use of field and telephone interviews
   to capture insights and information from a wide range of industry experts and opinion leaders including:

       Executives from OTC firms in functional areas such as finance, production, procurement, sales, marketing,
       distribution, and research and development
       Suppliers of raw materials, packaging, and processing equipment
       Service providers such as advertising agencies, logistics providers, contract manufacturers and packagers, and
       retailers/distributors
       Key professionals specializing in manufacturing economics, packaging, chemicals, and technology assessment


   This report also draws upon nonconfidential data from Kline & Company's internal database, which contains nearly
   40 years of syndicated research on the nonprescription drugs industry. The analysis is supplemented by secondary
   research, including a review of annual reports and other financial files and analyses. This approach has proven to
   be the most effective and reliable approach to obtaining accurate data and expert insights.



   Kline Credentials
   Kline is a worldwide consulting and research firm dedicated to         Recently published or in-progress research for the
   providing the kind of insight and knowledge that helps companies       OTC industry includes:
   find a clear path to success. The firm has served the management          Nonprescription Drugs USA
   consulting and market research needs of organizations in the              OTC Innovations USA 1999-2009: Analysis of
                                                                             Factors for Success
   chemicals, materials, energy, life sciences, and consumer products
                                                                             Rx-to-OTC Switch Forecasts USA 2010
   industries for over 50 years.
                                                                             Impact of Recessions on the U.S. OTC Market
                                                                             Rx-to-OTC Switch Strategies USA
   Kline's research and consulting services extend across the entire         Personal Care: U.S. Competitor Cost Structures
   personal care industry value chain. Our solutions have helped             OTC Competitor Cost Structures USA 2006
   clients develop better ways to create and profit from new business        U.S. Cholesterol-Lowering Drugs 2005
   opportunities, respond to competitive and economic threats,               International Rx-to-OTC Switch Forecasts
   improve productivity, achieve sustainable growth, and optimize            Nonprescription Drugs Canada
                                                                             Retailer Perceptions of OTC Drug Marketers
   performance. Kline provides clients with facts, forecasts, and
                                                                             OTCs in Managed Care
   recommendations based solidly on the realities of the market.

   Our market research reports and services are designed to provide subscribers with a deeper understanding of their
   markets, an outlook for their business, and accurate information about their competitors. Our clients tell us they
   often use Kline's market research to validate their own internal analysis, and many clients rely on Kline reports as
   their most critical source of information.

   For more information about this study or Kline's other services, e-mail us at sales@klinegroup.com, visit our website
   at www.KlineGroup.com, or contact us at any of our regional offices listed below.
   North America       Latin America        Europe              Japan                  Asia                    India
   +1-973-435-6262     +55-11-3079-0792     +32-2-770-4740      +81-3-3242-6277        +86-21-6876-8600        +91-124-4546-100



  www.KlineGroup.com                                                              Report #Y617B | © 2011 Kline & Company, Inc.

Weitere ähnliche Inhalte

Mehr von Kline and Company

Professional Aesthetics: U.S. Market Analysis and Opportunities
Professional Aesthetics: U.S. Market Analysis and OpportunitiesProfessional Aesthetics: U.S. Market Analysis and Opportunities
Professional Aesthetics: U.S. Market Analysis and OpportunitiesKline and Company
 
Global Marine Lubricants: Market Analysis and Opportunities
Global Marine Lubricants: Market Analysis and OpportunitiesGlobal Marine Lubricants: Market Analysis and Opportunities
Global Marine Lubricants: Market Analysis and OpportunitiesKline and Company
 
OTC Consumer Shopper Insights - Brochure
OTC Consumer Shopper Insights - BrochureOTC Consumer Shopper Insights - Brochure
OTC Consumer Shopper Insights - BrochureKline and Company
 
Kline Consumer Mindset Mapping: Attitude Tracking Service for Cosmetics and T...
Kline Consumer Mindset Mapping: Attitude Tracking Service for Cosmetics and T...Kline Consumer Mindset Mapping: Attitude Tracking Service for Cosmetics and T...
Kline Consumer Mindset Mapping: Attitude Tracking Service for Cosmetics and T...Kline and Company
 
Food Service Cleaning Products: U.S. Market Analysis and Opportunities - Broc...
Food Service Cleaning Products: U.S. Market Analysis and Opportunities - Broc...Food Service Cleaning Products: U.S. Market Analysis and Opportunities - Broc...
Food Service Cleaning Products: U.S. Market Analysis and Opportunities - Broc...Kline and Company
 
Nonprescription Drugs USA - Brochure
Nonprescription Drugs USA - BrochureNonprescription Drugs USA - Brochure
Nonprescription Drugs USA - BrochureKline and Company
 
FlashPoint - Consumer Segmentation Series - Brochure
FlashPoint - Consumer Segmentation Series - BrochureFlashPoint - Consumer Segmentation Series - Brochure
FlashPoint - Consumer Segmentation Series - BrochureKline and Company
 
Global Lubricants - Brochure
Global Lubricants - BrochureGlobal Lubricants - Brochure
Global Lubricants - BrochureKline and Company
 
Natural Personal Care 2011 - Brochure
Natural Personal Care 2011 - BrochureNatural Personal Care 2011 - Brochure
Natural Personal Care 2011 - BrochureKline and Company
 
Global Wax Industry 2010 - Brochure
Global Wax Industry 2010 - BrochureGlobal Wax Industry 2010 - Brochure
Global Wax Industry 2010 - BrochureKline and Company
 
Global Lubricant Basestocks 2010 - Brochure
Global Lubricant Basestocks 2010 - BrochureGlobal Lubricant Basestocks 2010 - Brochure
Global Lubricant Basestocks 2010 - BrochureKline and Company
 
Global Lubricant Additives 2010 - Brochure
Global Lubricant Additives 2010 - BrochureGlobal Lubricant Additives 2010 - Brochure
Global Lubricant Additives 2010 - BrochureKline and Company
 
Global Lubricants 2010 - Brochure
Global Lubricants 2010 - BrochureGlobal Lubricants 2010 - Brochure
Global Lubricants 2010 - BrochureKline and Company
 
Nonprescription Drugs 2011 US - Brochure
Nonprescription Drugs 2011 US - BrochureNonprescription Drugs 2011 US - Brochure
Nonprescription Drugs 2011 US - BrochureKline and Company
 
Personal Care 2009 US Competitor Cost Structures - Fact sheet
Personal Care 2009 US Competitor Cost Structures - Fact sheetPersonal Care 2009 US Competitor Cost Structures - Fact sheet
Personal Care 2009 US Competitor Cost Structures - Fact sheetKline and Company
 
Natural Personal Care 2010 Global Series - Brochure
Natural Personal Care 2010 Global Series - BrochureNatural Personal Care 2010 Global Series - Brochure
Natural Personal Care 2010 Global Series - BrochureKline and Company
 

Mehr von Kline and Company (20)

Professional Aesthetics: U.S. Market Analysis and Opportunities
Professional Aesthetics: U.S. Market Analysis and OpportunitiesProfessional Aesthetics: U.S. Market Analysis and Opportunities
Professional Aesthetics: U.S. Market Analysis and Opportunities
 
Global Marine Lubricants: Market Analysis and Opportunities
Global Marine Lubricants: Market Analysis and OpportunitiesGlobal Marine Lubricants: Market Analysis and Opportunities
Global Marine Lubricants: Market Analysis and Opportunities
 
Consumer beauty preferences
Consumer beauty preferencesConsumer beauty preferences
Consumer beauty preferences
 
OTC Consumer Shopper Insights - Brochure
OTC Consumer Shopper Insights - BrochureOTC Consumer Shopper Insights - Brochure
OTC Consumer Shopper Insights - Brochure
 
Kline Consumer Mindset Mapping: Attitude Tracking Service for Cosmetics and T...
Kline Consumer Mindset Mapping: Attitude Tracking Service for Cosmetics and T...Kline Consumer Mindset Mapping: Attitude Tracking Service for Cosmetics and T...
Kline Consumer Mindset Mapping: Attitude Tracking Service for Cosmetics and T...
 
Health and Wellness Devices
Health and Wellness DevicesHealth and Wellness Devices
Health and Wellness Devices
 
Food Service Cleaning Products: U.S. Market Analysis and Opportunities - Broc...
Food Service Cleaning Products: U.S. Market Analysis and Opportunities - Broc...Food Service Cleaning Products: U.S. Market Analysis and Opportunities - Broc...
Food Service Cleaning Products: U.S. Market Analysis and Opportunities - Broc...
 
LubesNet Database
LubesNet DatabaseLubesNet Database
LubesNet Database
 
Nonprescription Drugs USA - Brochure
Nonprescription Drugs USA - BrochureNonprescription Drugs USA - Brochure
Nonprescription Drugs USA - Brochure
 
FlashPoint - Consumer Segmentation Series - Brochure
FlashPoint - Consumer Segmentation Series - BrochureFlashPoint - Consumer Segmentation Series - Brochure
FlashPoint - Consumer Segmentation Series - Brochure
 
Global Lubricants - Brochure
Global Lubricants - BrochureGlobal Lubricants - Brochure
Global Lubricants - Brochure
 
OTC Retailing US - Brochure
OTC Retailing US - BrochureOTC Retailing US - Brochure
OTC Retailing US - Brochure
 
Natural Personal Care 2011 - Brochure
Natural Personal Care 2011 - BrochureNatural Personal Care 2011 - Brochure
Natural Personal Care 2011 - Brochure
 
Global Wax Industry 2010 - Brochure
Global Wax Industry 2010 - BrochureGlobal Wax Industry 2010 - Brochure
Global Wax Industry 2010 - Brochure
 
Global Lubricant Basestocks 2010 - Brochure
Global Lubricant Basestocks 2010 - BrochureGlobal Lubricant Basestocks 2010 - Brochure
Global Lubricant Basestocks 2010 - Brochure
 
Global Lubricant Additives 2010 - Brochure
Global Lubricant Additives 2010 - BrochureGlobal Lubricant Additives 2010 - Brochure
Global Lubricant Additives 2010 - Brochure
 
Global Lubricants 2010 - Brochure
Global Lubricants 2010 - BrochureGlobal Lubricants 2010 - Brochure
Global Lubricants 2010 - Brochure
 
Nonprescription Drugs 2011 US - Brochure
Nonprescription Drugs 2011 US - BrochureNonprescription Drugs 2011 US - Brochure
Nonprescription Drugs 2011 US - Brochure
 
Personal Care 2009 US Competitor Cost Structures - Fact sheet
Personal Care 2009 US Competitor Cost Structures - Fact sheetPersonal Care 2009 US Competitor Cost Structures - Fact sheet
Personal Care 2009 US Competitor Cost Structures - Fact sheet
 
Natural Personal Care 2010 Global Series - Brochure
Natural Personal Care 2010 Global Series - BrochureNatural Personal Care 2010 Global Series - Brochure
Natural Personal Care 2010 Global Series - Brochure
 

Kürzlich hochgeladen

Money Forward Integrated Report “Forward Map” 2024
Money Forward Integrated Report “Forward Map” 2024Money Forward Integrated Report “Forward Map” 2024
Money Forward Integrated Report “Forward Map” 2024Money Forward
 
ΤτΕ: Ανάπτυξη 2,3% και πληθωρισμός 2,8% φέτος
ΤτΕ: Ανάπτυξη 2,3% και πληθωρισμός 2,8% φέτοςΤτΕ: Ανάπτυξη 2,3% και πληθωρισμός 2,8% φέτος
ΤτΕ: Ανάπτυξη 2,3% και πληθωρισμός 2,8% φέτοςNewsroom8
 
Introduction to Health Economics Dr. R. Kurinji Malar.pptx
Introduction to Health Economics Dr. R. Kurinji Malar.pptxIntroduction to Health Economics Dr. R. Kurinji Malar.pptx
Introduction to Health Economics Dr. R. Kurinji Malar.pptxDrRkurinjiMalarkurin
 
Thoma Bravo Equity - Presentation Pension Fund
Thoma Bravo Equity - Presentation Pension FundThoma Bravo Equity - Presentation Pension Fund
Thoma Bravo Equity - Presentation Pension FundAshwinJey
 
OAT_RI_Ep18 WeighingTheRisks_Mar24_GlobalCredit.pptx
OAT_RI_Ep18 WeighingTheRisks_Mar24_GlobalCredit.pptxOAT_RI_Ep18 WeighingTheRisks_Mar24_GlobalCredit.pptx
OAT_RI_Ep18 WeighingTheRisks_Mar24_GlobalCredit.pptxhiddenlevers
 
Uk-NO1 Rohani Amil In Islamabad Amil Baba in Rawalpindi Kala Jadu Amil In Raw...
Uk-NO1 Rohani Amil In Islamabad Amil Baba in Rawalpindi Kala Jadu Amil In Raw...Uk-NO1 Rohani Amil In Islamabad Amil Baba in Rawalpindi Kala Jadu Amil In Raw...
Uk-NO1 Rohani Amil In Islamabad Amil Baba in Rawalpindi Kala Jadu Amil In Raw...Amil baba
 
Zimbabwe's New Gold-Backed Currency- A Path to Stability or Another Monetary.pdf
Zimbabwe's New Gold-Backed Currency- A Path to Stability or Another Monetary.pdfZimbabwe's New Gold-Backed Currency- A Path to Stability or Another Monetary.pdf
Zimbabwe's New Gold-Backed Currency- A Path to Stability or Another Monetary.pdfFREELANCER
 
2B Nation-State.pptx contemporary world nation
2B  Nation-State.pptx contemporary world nation2B  Nation-State.pptx contemporary world nation
2B Nation-State.pptx contemporary world nationko9240888
 
Banking: Commercial and Central Banking.pptx
Banking: Commercial and Central Banking.pptxBanking: Commercial and Central Banking.pptx
Banking: Commercial and Central Banking.pptxANTHONYAKINYOSOYE1
 
Demographic transition and the rise of wealth inequality
Demographic transition and the rise of wealth inequalityDemographic transition and the rise of wealth inequality
Demographic transition and the rise of wealth inequalityGRAPE
 
Building pressure? Rising rents, and what to expect in the future
Building pressure? Rising rents, and what to expect in the futureBuilding pressure? Rising rents, and what to expect in the future
Building pressure? Rising rents, and what to expect in the futureResolutionFoundation
 
ekthesi-trapeza-tis-ellados-gia-2023.pdf
ekthesi-trapeza-tis-ellados-gia-2023.pdfekthesi-trapeza-tis-ellados-gia-2023.pdf
ekthesi-trapeza-tis-ellados-gia-2023.pdfSteliosTheodorou4
 
What is sip and What are its Benefits in 2024
What is sip and What are its Benefits in 2024What is sip and What are its Benefits in 2024
What is sip and What are its Benefits in 2024prajwalgopocket
 
2024-04-09 - Pension Playpen roundtable - slides.pptx
2024-04-09 - Pension Playpen roundtable - slides.pptx2024-04-09 - Pension Playpen roundtable - slides.pptx
2024-04-09 - Pension Playpen roundtable - slides.pptxHenry Tapper
 
10 QuickBooks Tips 2024 - Globus Finanza.pdf
10 QuickBooks Tips 2024 - Globus Finanza.pdf10 QuickBooks Tips 2024 - Globus Finanza.pdf
10 QuickBooks Tips 2024 - Globus Finanza.pdfglobusfinanza
 
Global Economic Outlook, 2024 - Scholaride Consulting
Global Economic Outlook, 2024 - Scholaride ConsultingGlobal Economic Outlook, 2024 - Scholaride Consulting
Global Economic Outlook, 2024 - Scholaride Consultingswastiknandyofficial
 
TACLOBAN-CITY-DIVISION-POPQUIZ-2023.pptx
TACLOBAN-CITY-DIVISION-POPQUIZ-2023.pptxTACLOBAN-CITY-DIVISION-POPQUIZ-2023.pptx
TACLOBAN-CITY-DIVISION-POPQUIZ-2023.pptxKathlynVillar
 
Aon-UK-DC-Pension-Tracker-Q1-2024. slideshare
Aon-UK-DC-Pension-Tracker-Q1-2024. slideshareAon-UK-DC-Pension-Tracker-Q1-2024. slideshare
Aon-UK-DC-Pension-Tracker-Q1-2024. slideshareHenry Tapper
 
Hello this ppt is about seminar final project
Hello this ppt is about seminar final projectHello this ppt is about seminar final project
Hello this ppt is about seminar final projectninnasirsi
 

Kürzlich hochgeladen (19)

Money Forward Integrated Report “Forward Map” 2024
Money Forward Integrated Report “Forward Map” 2024Money Forward Integrated Report “Forward Map” 2024
Money Forward Integrated Report “Forward Map” 2024
 
ΤτΕ: Ανάπτυξη 2,3% και πληθωρισμός 2,8% φέτος
ΤτΕ: Ανάπτυξη 2,3% και πληθωρισμός 2,8% φέτοςΤτΕ: Ανάπτυξη 2,3% και πληθωρισμός 2,8% φέτος
ΤτΕ: Ανάπτυξη 2,3% και πληθωρισμός 2,8% φέτος
 
Introduction to Health Economics Dr. R. Kurinji Malar.pptx
Introduction to Health Economics Dr. R. Kurinji Malar.pptxIntroduction to Health Economics Dr. R. Kurinji Malar.pptx
Introduction to Health Economics Dr. R. Kurinji Malar.pptx
 
Thoma Bravo Equity - Presentation Pension Fund
Thoma Bravo Equity - Presentation Pension FundThoma Bravo Equity - Presentation Pension Fund
Thoma Bravo Equity - Presentation Pension Fund
 
OAT_RI_Ep18 WeighingTheRisks_Mar24_GlobalCredit.pptx
OAT_RI_Ep18 WeighingTheRisks_Mar24_GlobalCredit.pptxOAT_RI_Ep18 WeighingTheRisks_Mar24_GlobalCredit.pptx
OAT_RI_Ep18 WeighingTheRisks_Mar24_GlobalCredit.pptx
 
Uk-NO1 Rohani Amil In Islamabad Amil Baba in Rawalpindi Kala Jadu Amil In Raw...
Uk-NO1 Rohani Amil In Islamabad Amil Baba in Rawalpindi Kala Jadu Amil In Raw...Uk-NO1 Rohani Amil In Islamabad Amil Baba in Rawalpindi Kala Jadu Amil In Raw...
Uk-NO1 Rohani Amil In Islamabad Amil Baba in Rawalpindi Kala Jadu Amil In Raw...
 
Zimbabwe's New Gold-Backed Currency- A Path to Stability or Another Monetary.pdf
Zimbabwe's New Gold-Backed Currency- A Path to Stability or Another Monetary.pdfZimbabwe's New Gold-Backed Currency- A Path to Stability or Another Monetary.pdf
Zimbabwe's New Gold-Backed Currency- A Path to Stability or Another Monetary.pdf
 
2B Nation-State.pptx contemporary world nation
2B  Nation-State.pptx contemporary world nation2B  Nation-State.pptx contemporary world nation
2B Nation-State.pptx contemporary world nation
 
Banking: Commercial and Central Banking.pptx
Banking: Commercial and Central Banking.pptxBanking: Commercial and Central Banking.pptx
Banking: Commercial and Central Banking.pptx
 
Demographic transition and the rise of wealth inequality
Demographic transition and the rise of wealth inequalityDemographic transition and the rise of wealth inequality
Demographic transition and the rise of wealth inequality
 
Building pressure? Rising rents, and what to expect in the future
Building pressure? Rising rents, and what to expect in the futureBuilding pressure? Rising rents, and what to expect in the future
Building pressure? Rising rents, and what to expect in the future
 
ekthesi-trapeza-tis-ellados-gia-2023.pdf
ekthesi-trapeza-tis-ellados-gia-2023.pdfekthesi-trapeza-tis-ellados-gia-2023.pdf
ekthesi-trapeza-tis-ellados-gia-2023.pdf
 
What is sip and What are its Benefits in 2024
What is sip and What are its Benefits in 2024What is sip and What are its Benefits in 2024
What is sip and What are its Benefits in 2024
 
2024-04-09 - Pension Playpen roundtable - slides.pptx
2024-04-09 - Pension Playpen roundtable - slides.pptx2024-04-09 - Pension Playpen roundtable - slides.pptx
2024-04-09 - Pension Playpen roundtable - slides.pptx
 
10 QuickBooks Tips 2024 - Globus Finanza.pdf
10 QuickBooks Tips 2024 - Globus Finanza.pdf10 QuickBooks Tips 2024 - Globus Finanza.pdf
10 QuickBooks Tips 2024 - Globus Finanza.pdf
 
Global Economic Outlook, 2024 - Scholaride Consulting
Global Economic Outlook, 2024 - Scholaride ConsultingGlobal Economic Outlook, 2024 - Scholaride Consulting
Global Economic Outlook, 2024 - Scholaride Consulting
 
TACLOBAN-CITY-DIVISION-POPQUIZ-2023.pptx
TACLOBAN-CITY-DIVISION-POPQUIZ-2023.pptxTACLOBAN-CITY-DIVISION-POPQUIZ-2023.pptx
TACLOBAN-CITY-DIVISION-POPQUIZ-2023.pptx
 
Aon-UK-DC-Pension-Tracker-Q1-2024. slideshare
Aon-UK-DC-Pension-Tracker-Q1-2024. slideshareAon-UK-DC-Pension-Tracker-Q1-2024. slideshare
Aon-UK-DC-Pension-Tracker-Q1-2024. slideshare
 
Hello this ppt is about seminar final project
Hello this ppt is about seminar final projectHello this ppt is about seminar final project
Hello this ppt is about seminar final project
 

OTC Drugs: Competitor Cost Structures 2010 US - Brochure

  • 1. Healthcare In-Depth Report Series OTC Drugs: U.S. Competitor Cost Structures 2010 8th Edition One of Kline's series of reports on competitor cost structures Published September 2010 Base Year: 2008 and 2009 An accurate and comprehensive examination of competitor cost structures of leading OTC marketers, focusing on key trends, developments, and business opportunities designed to: Understand how key marketers' cost structures have changed during the recession Offer a benchmark for industry cost performance Reveal profit and loss line items for each players' OTC business and their largest product classes Assess the cost positions of market leaders including Johnson & Johnson, Pfizer, Bayer Group, and GlaxoSmithKline Give subscribers critical insights in order to succeed in the face of intensifying cost pressures Provide an appraisal of expected future performance www.KlineGroup.com Report #Y617B | © 2011 Kline & Company, Inc.
  • 2. OTC Drugs: U.S. Competitor Cost Structures 2010 Report Scope OTC Drugs: U.S. Competitor Cost Structures 2010 has been successfully completed seven times before and was last published in 2006. The report presents information on the financial performance, profitability, and costs structures of the ten leading OTC companies in the United States. It is designed to help OTC pharmaceutical companies benchmark their cost structures with those of their competitors. For each company, cost breakdowns are provided for its overall OTC business, as well as its leading product classes. Company profiles also feature overviews of each company's OTC business unit, an assessment of domestic OTC sales by product class, and analysis of costs, expenses, and profitability. Cost structures refer to U.S. operations only. Sales, expenses, and profits are presented for 2008 and 2009 and do not include extraordinary or nonrecurring items reports in published financial statements. References to overall corporate results are for the latest fiscal year available. Key Benefits This study provides subscribers with accurate and concise profitability information and cost structures of 10 major OTC marketers in the United States. It is designed to help nonprescription drugs firms benchmark their cost structures with those of their competitors. Specifically, this report assists subscribers by providing: Line-item detail to allow companies to benchmark their business against that of competitors Details on how OTC marketers structure and run their operations Insights into decisions companies have made regarding outsourcing, resource allocation, and product portfolios Competitive intelligence that helps companies make decisions to take steps to lower costs Important comparisons of marketers' cost structures between 2005, 2008, and 2009 and understanding how OTC marketers are coping with the recession by shifting their costs www.KlineGroup.com Report #Y617B | © 2011 Kline & Company, Inc.
  • 3. OTC Drugs: U.S. Competitor Cost Structures 2010 Report Contents 1. INTRODUCTION 2. EXECUTIVE SUMMARY State of the industry Impacts on the industry from the recession Market sales and growth Industry cost structure Key factors influencing profitability Analysis of key expenses Competitive landscape/ impact of mergers on costs structures Product class cost structures (for those listed in Table 1) Appraisal and Outlook 3. COMPANY PROFILES For each of the companies profiled (listed in Table 2), the report provides information on profitability for its OTC business unit and leading product classes (illustrated in Table 3) and includes: Corporate overview Corporate sales and profits Business unit cost structure – Profitability – Analysis of key expenses Cost structure of leading product classes Appraisal Table 1: Product Classes Covered Table 3: Cost Structure of the OTC Industry Line item % Of net sales Allergy, asthma, Nutritional products NET SALES and sinus medications Topical products COST OF GOODS SOLD Cough and cold preparations Other products, including home Raw materials Digestive products diagnostic test kits, sleeping Packaging aids, smoking cessation aids, Processing Feminine products Overhead and weight loss medications Internal analgesics Total GROSS MARGIN MARKETING EXPENSES Promotion Trade Consumer Table 2: Companies Profiled Total Advertising Bayer Group Perrigo Marketing department GlaxoSmithKline Pfizer Sales force/sampling Distribution Johnson & Johnson Procter & Gamble Total Merck Reckitt Benckiser MARGIN AFTER MARKETING EXPENSES Novartis Sanofi-Aventis OTHER OPERATING EXPENSES Administration Research and development Total OPERATING MARGIN www.KlineGroup.com Report #Y617B | © 2011 Kline & Company, Inc.
  • 4. OTC Drugs: U.S. Competitor Cost Structures 2010 Methodology Kline is unmatched in our ability to gather hard-to-get market and competitive intelligence with a high degree of confidence. Kline's approach relies heavily on primary research, employing the use of field and telephone interviews to capture insights and information from a wide range of industry experts and opinion leaders including: Executives from OTC firms in functional areas such as finance, production, procurement, sales, marketing, distribution, and research and development Suppliers of raw materials, packaging, and processing equipment Service providers such as advertising agencies, logistics providers, contract manufacturers and packagers, and retailers/distributors Key professionals specializing in manufacturing economics, packaging, chemicals, and technology assessment This report also draws upon nonconfidential data from Kline & Company's internal database, which contains nearly 40 years of syndicated research on the nonprescription drugs industry. The analysis is supplemented by secondary research, including a review of annual reports and other financial files and analyses. This approach has proven to be the most effective and reliable approach to obtaining accurate data and expert insights. Kline Credentials Kline is a worldwide consulting and research firm dedicated to Recently published or in-progress research for the providing the kind of insight and knowledge that helps companies OTC industry includes: find a clear path to success. The firm has served the management Nonprescription Drugs USA consulting and market research needs of organizations in the OTC Innovations USA 1999-2009: Analysis of Factors for Success chemicals, materials, energy, life sciences, and consumer products Rx-to-OTC Switch Forecasts USA 2010 industries for over 50 years. Impact of Recessions on the U.S. OTC Market Rx-to-OTC Switch Strategies USA Kline's research and consulting services extend across the entire Personal Care: U.S. Competitor Cost Structures personal care industry value chain. Our solutions have helped OTC Competitor Cost Structures USA 2006 clients develop better ways to create and profit from new business U.S. Cholesterol-Lowering Drugs 2005 opportunities, respond to competitive and economic threats, International Rx-to-OTC Switch Forecasts improve productivity, achieve sustainable growth, and optimize Nonprescription Drugs Canada Retailer Perceptions of OTC Drug Marketers performance. Kline provides clients with facts, forecasts, and OTCs in Managed Care recommendations based solidly on the realities of the market. Our market research reports and services are designed to provide subscribers with a deeper understanding of their markets, an outlook for their business, and accurate information about their competitors. Our clients tell us they often use Kline's market research to validate their own internal analysis, and many clients rely on Kline reports as their most critical source of information. For more information about this study or Kline's other services, e-mail us at sales@klinegroup.com, visit our website at www.KlineGroup.com, or contact us at any of our regional offices listed below. North America Latin America Europe Japan Asia India +1-973-435-6262 +55-11-3079-0792 +32-2-770-4740 +81-3-3242-6277 +86-21-6876-8600 +91-124-4546-100 www.KlineGroup.com Report #Y617B | © 2011 Kline & Company, Inc.